Zydus Lifesciences Sees 9% Rise in Q4FY26 Net Profit to Rs 1,272.5 Crore

Zydus Lifesciences Reports Strong Q4FY26 Performance Amid One-Time Expenses

Zydus Lifesciences, a leading pharmaceutical company, has posted a rise in reported net profit for Q4FY26, despite a sharp increase in one-off expenses, driven by strong operational performance and margin expansion.

The company reported a net profit of Rs 1,272.5 crore, up 8.7 percent year-on-year, while adjusted net profit rose 15 percent to Rs 1,592.9 crore, reflecting underlying strength across key businesses. The divergence between reported and adjusted profit was driven by a Rs 397.5 crore one-time expense related to a Mirabegron litigation settlement, alongside other exceptional costs during the quarter.

Revenue from operations rose 16 percent year-on-year to Rs 7,587 crore, while EBITDA grew faster at 20 percent, expanding margins by 110 basis points to 33.7 percent.

Read also: Treasury Yields Experience Largest Increase in Two Weeks Following Release of Labor Market Data

The margin improvement came despite elevated investments—particularly in R&D, which rose to 9.2 percent of revenue—and higher operating costs, indicating stronger gross performance and operating leverage. Growth was led by a mix of domestic formulations, consumer wellness, and international markets.

India formulations grew 14 percent year-on-year to Rs 1,752.8 crore, continuing to outpace the broader market, led by chronic therapies and specialty segments such as oncology and nephrology. International markets surged 45 percent to Rs 804 crore, driven by demand across emerging markets and Europe. Consumer wellness stood out with a sharp 61 percent jump, aided by strong performance in international business and select categories like skin and nutrition.

However, growth in the core US generics business remained muted. North America formulations declined 6 percent year-on-year, reflecting pricing pressure, even as sequential growth was supported by new launches and base business traction.

Read also: US-Iran Tensions Spark Uptick in Oil Prices Amid Global Market Decline

The company has approved a buyback of up to Rs 1,100 crore at Rs 1,150 per share, along with a 100 percent dividend for FY26. The investor presentation underscored Zydus’ pivot toward diversified growth engines beyond generics, including consumer health, specialty pharmaceuticals, and MedTech. Consumer wellness now contributes about 20 percent of revenues, while MedTech—still small—has begun scaling.

At the same time, Zydus continues to invest aggressively in innovation, with ongoing biosimilar launches, novel drug development, and global filings, reinforcing its transition toward a research-led model. Share of Zydus rose 2.80 percent to Rs 1,018.95 at 3:50 pm on BSE on Tuesday, while the benchmark Sensex declined 0.15 percent to 75,200 points.